Role and Significance of Markers of Inflammation in the Asthmatic Disease
DOI:
https://doi.org/10.3889/oamjms.2015.109Keywords:
asthma, markers, inflammation, eosinophil, eosinophil cationic protein, IL-5Abstract
BACKGROUND: Asthma is characterized by airway inflammation which can be reversible.
AIM: Investigation the importance of eosinophils, ECP and IL-5 in asthmatics versus patients with obstructive bronchitis and healthy subjects. We investigated the values before and after the treatment in asthmatics.
MATERIAL AND METHODS: We studied 77 subjects divided in three groups as follows: 1) asthma patients; 2) patients with obstructive bronchitis and 3) control group of healthy subjects. In all the subjects there were determined: Total number of eosinophils (Eo), eosinophilic cationic protein (ECP), Interleukin 5 (IL-5) and allergy tests.
RESULTS: The total number of eosinophils was significantly increased in the group of asthma patients versus second and third group. We found that the presence of ECP demonstrate an ongoing inflammation, with or without clinical symptoms of asthma patients. There was significant difference between the values of ECP of asthma patients versus second and third group. Our results have shown that IL-5 was significantly increased versus second group and controls (p < 0.01). We also found the decrease of the values of inflammatory markers after the treatment with corticosteroids.
CONCLUSIONS: Eosinophils, ECP and IL-5 could be useful markers for selecting allergic patients and could be the monitors of treatment effects.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Global Initiative for Asthma (GINA). GINA Report 2014, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2014.
World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007.
World Allergy Organization (WAO) .White Book on Allergy, 2011.
Gjorcev A. Macedonian National Consensus for Diagnosis and Treatment of Asthma - Reality and Perspective, 1996.
Cvetanov V. Allergic Diseases in R. Macedonia, 2006: 151- 174.
Busee WW, Lemanske RFJr. Asthma. New Engl J Med. 2001;344:350-362.
http://dx.doi.org/10.1056/NEJM200102013440507 DOI: https://doi.org/10.1056/NEJM200102013440507
PMid:11172168
Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720-45.
http://dx.doi.org/10.1164/ajrccm.161.5.9903102 DOI: https://doi.org/10.1164/ajrccm.161.5.9903102
PMid:10806180
Murray and Nadel's Textbook of Respiratory Medicine, 4th Ed. Robert J. Mason, John F. Murray, Jay A. Nadel. Elsevier, 2005: pp. 334.
Weller PF. The Immunobiology of Eosinophils. N Engl J Med. 1991;324:1110-1118.
http://dx.doi.org/10.1056/NEJM199104183241607 DOI: https://doi.org/10.1056/NEJM199104183241607
PMid:2008184
Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldman M, Tavernier J, Capron A, Capron M. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 1994;179(2):703-8.
http://dx.doi.org/10.1084/jem.179.2.703 DOI: https://doi.org/10.1084/jem.179.2.703
PMid:8294877
Motojima S, Akutsu I, Fukuda T, Makino S, Takatsu K. Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma. Allergy. 1993;48:98-106.
http://dx.doi.org/10.1111/j.1398-9995.1993.tb04709.x DOI: https://doi.org/10.1111/j.1398-9995.1993.tb04709.x
PMid:8109721
Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2007;101(4):696-705.
http://dx.doi.org/10.1016/j.rmed.2006.08.012 DOI: https://doi.org/10.1016/j.rmed.2006.08.012
PMid:17034998
Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Report 2015, Global Strategy for Diagnosis, Management, and Prevention of COPD. Updated 2015
Bousquet J, Corrigan CJ, Venge P. Peripheral blood markers: evaluation on inflammation in asthma. Eur Resp J. 1998;11(Suppl. 26):42s-48s.
Dahl R. Monitoring of bronchial asthma in the blood. Allergy. 1993:48:77-80.
http://dx.doi.org/10.1111/j.1398-9995.1993.tb04704.x DOI: https://doi.org/10.1111/j.1398-9995.1993.tb04704.x
PMid:8109717
de Blay F, Purohit A, Stenger R, Gries P, Hamberger C, David B, Frossard N, Pauli G. Serum eosinophil cationic protein measurements in the management of perennial and periodic asthma: a prospective study. Eur Respir J. 1998;11(3):594-8.
PMid:9596108
Egan RW, Umland SP, Cuss FM, Chapman RW. Biology of interleukin-5 and its relevance to allergic disease. Allergy. 1996;51:71-81.
http://dx.doi.org/10.1111/j.1398-9995.1996.tb04561.x DOI: https://doi.org/10.1111/j.1398-9995.1996.tb04561.x
PMid:8738511
Fabbri LM, Durham S, Holgate S, Byrne PM, Postma DS. Assessment of airway inflammation: an overview. Eur Resp J. 1998:11(Suppl. 26):6s-8s.
Ronchi MC, Piragino C, Rosi E, Stendardi L, Tanini A, Galli G, Duranti R, Scano G. Do sputum eosinophils and ECP relate to the severity of asthma? Eur Respir J. 1997;10(8):1809-13.
http://dx.doi.org/10.1183/09031936.97.10081809 DOI: https://doi.org/10.1183/09031936.97.10081809
PMid:9272923
Vatrella A, Ponticiello A, Parrella R, Romano L, Zofra S, DiLeva A, Bariffi F. Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma. Allergy. 1996;51(8):547-55.
http://dx.doi.org/10.1111/j.1398-9995.1996.tb00111.x DOI: https://doi.org/10.1111/j.1398-9995.1996.tb00111.x
Barnes KC. Atopy and asthma genes-where do we stand? Allergy. 2000;55:803-817.
http://dx.doi.org/10.1034/j.1398-9995.2000.00123.x DOI: https://doi.org/10.1034/j.1398-9995.2000.00123.x
PMid:11003444
Hirokazu O, et al. IL-5 regulation – A New Approach to Allergy Therapy. Allergy and Clin Immun International. 1996;8(5&6):172-179.
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0